BRIEF published on 04/07/2026 at 07:05, 7 days 4 hours ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 7 days 4 hours ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 7 days 4 hours ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 7 days 4 hours ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 24 days 1 hour ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 24 days 1 hour ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 24 days 1 hour ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 24 days 1 hour ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 3 months 2 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 3 months 2 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 04/14/2026 at 10:55, 32 minutes ago Waton Financial Marks One Year as a Listed Company with MOTA: A New Chapter in Human-AI Investment Collaboration
Published on 04/14/2026 at 09:05, 2 hours 22 minutes ago BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
Published on 04/14/2026 at 09:01, 2 hours 26 minutes ago Star Copper Fully Funded 15,000 Metre Drill Program Targets Maiden Resource in 2026
Published on 04/13/2026 at 23:15, 12 hours 12 minutes ago Relevant Gold Completes Strategic Financing; Embarks on Largest Drilling Program in Company History
Published on 04/13/2026 at 23:00, 12 hours 27 minutes ago Sterling Metals Announces Sale Of Sail Pond Project
Published on 04/14/2026 at 11:00, 27 minutes ago CATHAROS launches: Germany’s local marketplace for medical cannabis
Published on 04/14/2026 at 10:30, 56 minutes ago Baucor Boosts European Operations with Strategic Product Expansion
Published on 04/14/2026 at 10:00, 1 hour 27 minutes ago ARTCLINE achieves milestone in septic shock: Patient recruitment for the ReActIF-ICE study successfully completed
Published on 04/14/2026 at 10:00, 1 hour 27 minutes ago Waton Financial Marks One Year as a Listed Company with MOTA: A New Chapter in Human-AI Investment Collaboration
Published on 04/14/2026 at 08:30, 2 hours 57 minutes ago ALPOU - Groupe POULAILLON - Projet offre publique d'achat obligatoire
Published on 04/13/2026 at 19:14, 16 hours 12 minutes ago ALTAREA - Déclaration d’opérations sur actions propres
Published on 04/13/2026 at 18:15, 17 hours 12 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2026
Published on 04/13/2026 at 18:15, 17 hours 12 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2026
Published on 04/13/2026 at 18:09, 17 hours 17 minutes ago Infotel : Cessation et mise en œuvre d’un nouveau contrat de liquidité avec Invest Securities.
